Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Añadir filtros








Intervalo de año
1.
Journal of Zhejiang University. Science. B ; (12): 948-954, 2020.
Artículo en Inglés | WPRIM | ID: wpr-880736

RESUMEN

The aim of this study was to evaluate the safety of an antiviral regimen of protease inhibitors combined with Arbidol (umifenovir) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia patients. The genomic sequence of SARS-CoV-2 is highly homologous to that of SARS-CoV (Zhou et al., 2020). Previously published basic and clinical research on anti-SARS-CoV treatment found that lopinavir/ritonavir (LPV/r) could improve the prognosis of SARS patients (Chan et al., 2003; Chu et al., 2004). Darunavir (DRV) is another protease inhibitor that blocks the binding of SARS-CoV-2 to human angiotensin-converting enzyme 2 (Omotuyi et al., 2020). The broad-spectrum antiviral drug Arbidol (umifenovir) also shows in vitro anti-SARS-CoV activity (Khamitov et al., 2008).


Asunto(s)
Adulto , Femenino , Humanos , Masculino , Persona de Mediana Edad , COVID-19/tratamiento farmacológico , China , Darunavir , Combinación de Medicamentos , Indoles/uso terapéutico , Metabolismo de los Lípidos , Lopinavir , Inhibidores de Proteasas/uso terapéutico , Estudios Retrospectivos , Ritonavir , SARS-CoV-2/genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA